|
Sign Up
Home IP Life Science Financial Service Use Cases
Data
API Resources
Contact Us
  • Cross-Border E-commerce Appearance Infringement Query
  • Named Entity Recognition
  • OCR Recognition
  • Life Science Intelligent Data Governance
Named Entity Recognition
Using AI technology, it is possible to extract company entities and biomedical entities (including Drugs, Diseases, and Targets, abbreviated as DDT) quickly from patents, literature, news and other English and Chinese texts.
1
Input a text description
2
Digitalization
Log in to try, click toLogin/Register
Try the following examples:
新闻文本：2月21日消息，昆秦生物顺利完成数千万元融资，所获资金将用于该公司产品研发投入、产线运营及市场布局等。本轮融资由陕西汇科创新投资有限公司（以下简称陕创投）独家投资。昆秦生物是一家专注于重组蛋白药物的开发与转化，人用疫苗研发、生产及销售的生物医药公司。该公司核心技术来源于中国工程院院士、温州医科大学校长李校堃及其团队。李校堃院士团队在重组蛋白药物及疫苗的研究及转化深耕30余年，尤其是在细胞生长因子与疾病研究上取得了一系列具有代表性的原创成果，解决了系列理论与产业化技术难题，已推进成纤维细胞生长因子（FGFs）研制成功并投产。公开信息显示，昆秦生物自成立以来便专注于传统疫苗的升级换代和创新疫苗的研发，积极拓展产品管线，陆续研究开发了四价流感病毒裂解疫苗、人二倍体细胞狂犬疫苗、重组带状疱疹疫苗、通用流感疫苗和重组HPV疫苗等，同时以自身技术优势探索开发mRNA疫苗、新型佐剂疫苗以及新剂型疫苗等。根据投资方陕创投新闻稿，昆秦生物产品管线主要涵盖肿瘤治疗、心脑血管疾病治疗、创伤修复以及医学美容等重大疾病领域。
News Text:SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost all cancer types and cause intractable cancers such cases found in ovarian cancer, uterine cancer, esophageal cancer, etc. The p53 gene acts as the "guardian of the genome," detecting cellular DNA damage and inducing cell death. When mutated, the p53 gene loses its function, leading to resistance to existing anticancer drugs and rapid metastasis of cancer cells. While R&D attempts have been made to develop anticancer agents that target p53 mutated cancer cells, those attempts have failed to selectively kill p53 mutated cancer cells without damaging normal cells. Previous researches have shown evidences that niclosamide is a promising metabolic anticancer agent. Niclosamide can induce cancer cell death by regulating cancer cell metabolic pathways and can resolve drug resistance and cancer cell metastasis while minimizing side effects. It also enhances anticancer effects when used in combination therapy with existing anticancer drug.
专利文本：本发明提供五味子酚及其衍生物在制备治疗抑郁症药物中的应用及所制备的抗抑郁药物。所述应用剂量为每千克体重0.01‑30mg五味子酚或其衍生物，给药后60分钟内即可产生抗抑郁效果。给药5天后，低剂量和高剂量均产生显著的抗抑郁效果。本发明研究结果表明，在哺乳动物小鼠悬尾实验中，五味子酚或其衍生物具有快速抗抑郁症的功效，且比常规抗抑郁药物丙咪嗪更有效。本发明采用强迫游泳实验和小鼠悬尾实验作为药物筛选实验，同时进行了小鼠开野实验(Open field test)，以检验小鼠的自主活动性，避免中枢兴奋药的干扰。本发明的抗抑郁药物，具有抗抑郁效果显著、起效快、用药量少、副作用小等优点，有望成为快速、高效、新机制的抗抑郁新药。
Patent Text:Regression of Established Atherosclerotic Plaques, and Treating Sudden-Onset Asthma Attacks, using PARP Inhibitors\n\n\nA method is and inducing the regression of established atherosclerotic plaques. A method is disclosed for treating asthma, including treatment of an ongoing asthma attack. In both cases, treatment with PARP inhibitors, such as the PARP inhibitor TIQ-A (Thieno[2,3-c]isoquinolin-5-one), can lead to regression of existing disease and symptoms.\n\n\n1. A method for relieving symptoms of a sudden-onset asthma attack in a human; said method comprising administering an effective amount of a PARP inhibitor to a human who is experiencing an acute asthma attack, wherein said PARP inhibitor is administered from 0 hours to 12 hours after the beginning of the sudden-onset asthma attack.\n2. The method of claim 1, wherein the PARP inhibitor is administered from 0 hours to 6 hours after the beginning of the sudden-onset asthma attack.\n3. The method of claim 1, wherein the PARP inhibitor is administered from 0 hours to 1 hours after the beginning of the sudden-onset asthma attack.\n4. The method of claim 1, wherein the PARP inhibitor is selected from the group consisting of TIQ-A; AIQ; 3-AB; PJ-34; 1,5-Isoquinolinediol; 3-Methyl-5-AIQ hydrochloride; 4-Amino-1,8-naphthalimide; 4-Hydroxyquinazoline; 5-AIQ hydrochloride; 5-Iodo-6-amino-1,2-benzopyrone; 6(5H)-Phenanthridinone; EB-47 dihydrochloride dihydrate; NU1025; DR2313; BSI 401; BSI 201; AZD 2281; INO 1001; GPI 15427; GPI 16539; GPI 6150; DR2313; AG14361; NU1025; CEP 6800; AG 014699; ABT-888; minocycline; tetracycline; and derivatives of these compounds.\n5. The method of claim 1, wherein the PARP inhibitor is TIQ-A.\n6. The method of claim 1, wherein the PARP inhibitor is a PARP-1 inhibitor.\n7. A method for inducing the regression of one or more existing atherosclerotic plaques in a human; said method comprising administering an effective amount of a PARP inhibitor over time to a human who has previously been diagnosed with one or more atherosclerotic plaques; then assaying one or more of the plaques to confirm whether one or more of the existing plaques has regressed in response to the PARP inhibitor; and then, if said assaying step indicates that one or more of the plaques has regressed, continuing further administration of the PARP inhibitor for an additional time to induce further regression of one or more of the plaques.\n8. The method of claim 7, wherein the PARP inhibitor is selected from the group consisting of TIQ-A; AIQ; 3-AB; PJ-34; 1,5-Isoquinolinediol; 3-Methyl-5-AIQ hydrochloride; 4-Amino-1,8-naphthalimide; 4-Hydroxyquinazoline; 5-AIQ hydrochloride; 5-Iodo-6-amino-1,2-benzopyrone; 6(5H)-Phenanthridinone; EB-47 dihydrochloride dihydrate; NU1025; DR2313; BSI 401; BSI 201; AZD 2281; INO 1001; GPI 15427; GPI 16539; GPI 6150; DR2313; AG14361; NU1025; CEP 6800; AG 014699; ABT-888; minocycline; tetracycline; and derivatives of these compounds.\n9. The method of claim 7, wherein the PARP inhibitor is TIQ-A.\n10. The method of claim 7, wherein the PARP inhibitor is a PARP-1 inhibitor
Paper Text:In the Nagoya City University Hospital, the authors started an "Anti-cancer drug prescription support system" according to which physicians input the injection prescription order from the "regimen," together with the Outpatient Oncol. Unit established in May, 2007. To prepare the anti-cancer drug more safely, the authors constructed a new "Anti-cancer drug preparation support system (new system)" at the same time. The authors investigated and evaluated the time and accuracy required for the preparation between the old and new systems. In the old system, the authors used electronic calculators or manual methods to perform calculations in the prescription procedure. In the new system, notes are automatically printed out with the kind, amount, and extraction amount of the dissolution liquid according to the dosage of the given anti-cancer drug for the injection prescription. Therefore, even a person with little experience in the preparation can carry out the preparative procedure accurately and promptly. Moreover, this system improves the efficiency of the preparation and it is thought that the utility is high as a part of the risk management.